Akèy › Kansè renn (Kasinom selil renn) › Missouri › St. Louis
Etid klinik pou Kansè renn (Kasinom selil renn) nan St. Louis, MO
23 etid pou Kansè renn (Kasinom selil renn) ap chèche patisipan nan sit nan ak bò kote St. Louis (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Washington University Medicine, St Louis
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mercy Infusion Center - Chippewa, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- ak 4 plis
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Ap rekriteFaz 1/2
- Washington University in St. Louis, St Louis
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- Siteman Cancer Center-South County, St Louis
- ak 5 plis
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Ap rekriteFaz 1/2
- Washington University, St Louis
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Washington University, St Louis
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Ap rekriteFaz 3
- Washington University School of Medicine ( Site 0114), St Louis
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Ap rekriteFaz 1/2
- Washington University School of Medicine, St Louis
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- Washington University, St Louis
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Ap rekriteFaz 2
- Mercy Hospital South, St Louis
- Mercy Hospital Saint Louis, St Louis
- Cancer Care Center of O'Fallon, O'Fallon · 16 mi lwen
- ak 1 plis
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Ap rekriteFaz 1/2
- Siteman Cancer Center, St Louis
- Barnes-Jewish Hospital, St Louis
- Washington University School of Medicine - Siteman Cancer Center, St Louis
- ak 5 plis
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Ap rekriteFaz 3
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- Siteman Cancer Center-South County, St Louis
- ak 6 plis
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site, St Louis
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
IDOV-Immune for Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
Ap rekriteFaz 3
- Missouri Baptist Medical Center, St Louis
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Ap rekriteFaz 2
- Siteman Cancer Center, Washington University, St Louis
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Ap rekriteFaz 1
- Washington University Medical Campus, St Louis
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Washington University, St Louis
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Ap rekriteFaz 3
- Saint Louis Cancer and Breast Institute-South City, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- ak 4 plis
Etid Kansè renn (Kasinom selil renn) nan lòt vil
- Houston, TX35 etid
- New York City, NY27 etid
- Nashville, TN23 etid
- Dallas, TX23 etid
- Los Angeles, CA20 etid
- Boston, MA16 etid
- Baldwin Park, CA16 etid
- Philadelphia, PA15 etid
- Pittsburgh, PA15 etid
- Queens, NY15 etid
- Jacksonville, FL14 etid
- Cleveland, OH14 etid
Lòt etid nan St. Louis
- Kansè Poumon ki pa ti selil73 etid
- Kansè nan tete64 etid
- Kansè Metastatik54 etid
- Kansè kolorektal50 etid
- Kansè (tout kalite)46 etid
- Kansè pwostat46 etid
- Kansè poumon39 etid
- Kansè ovè38 etid
- Kansè pankreyas33 etid
- Kansè Endomèt29 etid
- Karsinòm selil skuamèz tèt ak kou28 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.